skip to main content

Bisphosphonate administration — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardMusculoskeletal TherapeuticsBisphosphonate administrationGPhC CRA

A patient with metastatic breast cancer is to start high-dose intravenous zoledronic acid and reports loose teeth plus an extraction planned next week. What is the best pharmacy intervention?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: EArrange dental assessment and preventive care before starting treatment

Osteonecrosis-of-the-jaw risk is greatest with potent intravenous bisphosphonates used for cancer, and dental disease or invasive procedures add risk. MHRA advises dental assessment before cancer bisphosphonate treatment and treatment of active oral problems where possible, coordinated with oncology. The risk is not eliminated by switching route, mouthwash or permanent avoidance of all routine dentistry.

Reference: MHRA: bisphosphonates and osteonecrosis of the jaw. https://www.gov.uk/drug-safety-update/bisphosphonates-osteonecrosis-of-the-jaw